• Home
  • GROK on Cannabis
  • COLD-GROW™
  • Patents
  • Books
  • Weaponized Cannabis
  • Blog/Articles
  • Photo Gallery
  • More
    • Home
    • GROK on Cannabis
    • COLD-GROW™
    • Patents
    • Books
    • Weaponized Cannabis
    • Blog/Articles
    • Photo Gallery
  • Home
  • GROK on Cannabis
  • COLD-GROW™
  • Patents
  • Books
  • Weaponized Cannabis
  • Blog/Articles
  • Photo Gallery

US Patent No. 9,585,867

Press Release- September 8, 2024

Press Release- September 8, 2024

West Palm Beach, FL


NON-LETHAL WEAPONIZED CANNABIS ™

Donated To The Public Domain


US Pat Ser No 9,585,867 


My name is Charles Ankner, and I’m the founder and senior steward of SAINT™ BRAND CANNABIS, and owner of US Pat Ser No 9,585,867 which protects a method of sedating a person or animal from a distance via an inventive ballistic dart and inventive cannabinoid sedation formulation.


From the patent:

“Advantageously, a humane cannabinoid formulation may be used as and for quickly and safely sedating a subject within a short period of time, thus making subduing, and if required, containing the subject safer for all involved.


Additionally, and depending upon the cannabinoid formulation, a human or animal may be quickly incapacitated or immobilized at a distance. The purpose of and for incapacitating or immobilizing a human or animal may be many and varied. It is contemplated that the fields of medicine, veterinary medicine and science, military combat, law enforcement, corrections, emergency response, mass casualty response, and similar fields of endeavor may benefit from cannabinoid sedative formulations, or a cannabinoid being added to or administered with known sedative formulations for medical, scientific, and industrial purposes. Other cannabinoid sedative formulations may be also used for scientific and industrial use improvement and purposes.


Advantageously however, CB1 receptors are absent in the medulla oblongata, the part of the brain stem responsible for autonomic respiratory and cardiovascular function. This is highly advantageous when cannabinoids are used for and as sedative and anesthetic formulations. Affecting or depressing autonomic respiratory and/or cardiovascular function has long been a limiting disadvantage of known sedative and anesthetic formulations. Fortunately, unless introduced at extremely toxic levels, CB1 agonist cannabinoids primarily leave autonomic respiratory and cardiovascular functions in humans and animals unaffected, due to the lack of CB1 receptors in the brain stem medulla oblongata.”


The broadest claim:


8.  A method of humanely incapacitating or immobilizing a human or animal comprising:

providing a formulation including a cannabinoid;


providing a delivery system comprising an injection step capable of dosing the recipient with the formulation at a distance which renders a recipient incapacitated or immobilized within a short period of time after dosing, and 


wherein the recipient remains incapacitated or immobilized for a long period of time-after dosing without irreparable harm to or the death of the recipient; and


immobilizing the recipient by using the delivery system to dose the recipient with said formulation.


This was my first “personal” patent granted; filed in 2015, granted in 2017, and if maintained set for expiration in 2035.


For a few reasons; I’ve decided to allow the patent lapse and fall into the public domain.


First, I was a bit before my time.  Cannabis has remained a Class I Controlled Substance. I was not under any delusion that I could personally bring “such a thing” to market; although my private R&D was extensive.


I had approached several pharmaceutical companies exploring purchase of the patent and/or a strategic alliance to further develop the formulation - no dice. Under present cannabis prohibition; darting/injecting someone at a distance with NON-LETHAL WEAPONIZED CANNABIS™ …was an idea whose time had just not yet come.


Second, the “patent family remains alive” with my US Pat App Ser No 17/494,469 (heading to Appeal), and two other “strategically abandoned” applications, US 15/399,428 and 15/412,211.

I plan to “pick those back up again” within a few years and hopefully after government overreach related to cannabis is a thing of the past, file new CIP applications.


Third, by allowing the invention to enter the public domain, anyone globally may now develop the technology further. Modern methods are just now beginning to be applied to cannabis related scientific, medical, and industrial endeavors.


The more I study and invent related to cannabis and cannabinoids; the more convinced I am that the benefits of “this weed” will greatly mitigate the pain and suffering which plagues the present “human condition”. 


My prayer is that those with the wherewithal will further develop injectable cannabinoid formulations for various benevolent and beneficial objectives and outcomes. Grant this O’ Lord.


Sincerely and respectfully,


Charles Ankner,

Web: www.SaintBrandCannabis.com

Email: charles@saintbrandcannabis.com

Tel in US: 805.598.3422


Copyright © 2024 Charles Ankner Social Enterprises, LLC.

Appeal won! US Patent No. 12,656,092

Ballistic Delivery Method and System For Injectable Formulations

 

Abstract

A system and method of humanely dosing a human or animal with a formulation at a distance. A system capable of dosing a recipient with a formulation having a mass between 10 and 500 grains propelled at low-to-medium ballistic velocities (300 to 800 feet per second) and with medium-to-long range ballistic accuracy (10 to over 100 yards) without causing serious physical harm to, nor the death of, the recipient.

 

Claims

1. A spiraling ballistic flight projectile injection system for dosing a human or animal recipient with a formulation via injection at a ballistic distance, the system comprising: 


a housing having a longitudinal axis, a distal end, and a proximal end, wherein 


said housing has at least one cavity storing the formulation and at least one distal outlet port through which the formulation exits said housing; 


an injector head having a distal end, a proximal end, and a longitudinal axis in common with the housing longitudinal axis, including 


at least one proximal inlet port fluidly connected to the at least one distal outlet port of the housing, and including 


at least one curved distal hypodermic needle extending distally from the injector head offset from the housing and injector head longitudinal axis, 


the injector head proximal end mounted to the housing distal end along the housing and injector head longitudinal axis via a rotatable hub, 


the rotatable hub configured to allow the injector head to spin along the common longitudinal axis in respect to the housing, and wherein 


upon spiraling ballistic contact with the recipient, the at least one curved distal hypodermic needle, cooperatively with the direction of rotation of the housing and injector head along the common longitudinal axis of the housing and injector head, penetrates the dermis of the recipient to a depth facilitative of and suitable for subdermal bolus injection of the formulation, wherein 


the injector head when impacting the recipient constructively stops both distal and rotational movement along the common longitudinal axis, wherein 


the formulation exits the at least one cavity and passes through the at least one distal outlet port of the housing into the at least one proximal inlet port of the injector head and through the at least one curved distal hypodermic needle, 


so that the recipient is injected with the formulation without causing serious injury to or the death of the recipient.


2. The system of claim 1, wherein said projectile injection system is propelled by the group consisting of single-shot, semi-automatic, or fully automatic revolvers, pistols, shotguns, scatterguns, rifles, and combinations thereof.


3. The system of claim 1, wherein the housing further includes a plunger and a housing vent, wherein the housing vent allows for housing pressure equalization when and as the plunger displaces resulting in the injection of the formulation into the recipient.


4. The system of claim 1, wherein the injection system comprises a turbine or worm gear in communication with the rotatable hub, wherein when the housing continues rotation as the injector head remains constructively stationary, the turbine or worm gear forces the formulation through the at least one outlet port resulting in the injection of the formulation into the recipient.


5. The system of claim 1, wherein the system is reusable.


6. The system of claim 1, wherein the injector system utilizes inertial forces upon impact of the injector head with the recipient resulting in the injection of the formulation into the recipient.


7. The system of claim 4, wherein the housing further includes a worm gear along the common longitudinal axis in communication with the plunger and in communication with the rotatable hub, whereby the continuing rotation of the housing along the common longitudinal axis in relation to the hypodermic injector head and after impact with the recipient causes the plunger to displace along the common longitudinal axis resulting in the injection of the formulation.


8. The system of claim 4, wherein the housing further includes a gas under pressure, wherein when the gas is suddenly released, or comprises an explosive substance whereby when ignited expands, or comprises a spring under compression whereby when suddenly released, causes the plunger to displace resulting in the injection of the formulation.


9. The system of claim 1, wherein the at least one hypodermic needle further includes a barb.


10. The system of claim 1, wherein the at least one hypodermic needle is configured in an arc.


11. The system of claim 10, wherein the at least one hypodermic needle is configured in one or more cycloidal, epicycloidal, hypocycloidal, or other spiral arc.


12. The system of claim 1, wherein the injector head further comprises at least one cooperative strut corresponding to the at least one hypodermic needle and configured in such a manner as to facilitate dermal penetration of the recipient by the at least one hypodermic needle and to facilitate the injection of the formulation into the recipient.


13. The system of claim 1, wherein the outer circumference of the projectile injection system changes during ballistic flight.


14. The system of claim 1, wherein the outer circumference of the projectile injection system changes after impacting the recipient.


15. The system of claim 1, wherein the rotatable hub further includes or operates as a clutch between the housing and the injector head.


16. The system of claim 1, wherein the injector head further includes an airfoil.

Veterinary uses represent one of the strongest and most immediately promising applications for this ballistic delivery system. The patent explicitly contemplates use in veterinary medicine, zoology, zoo-keeping, animal husbandry, animal control, and related fields, building on longstanding needs for remote, humane immobilization, medication, or sedation of animals.


Current Context in Veterinary Practice

Traditional remote drug delivery in veterinary work relies heavily on dart guns/projectors (often CO2-powered or similar) and blowpipes. These deliver hypodermic darts containing sedatives, anesthetics, vaccines, antibiotics, or other injectables. Common applications include wildlife immobilization/capture, zoo animal procedures, livestock treatment, and rescue of injured or dangerous animals.


Limitations of existing systems include:

  • Effective ranges often limited to ~40–100 meters (optimized around 70 m in many cases), with accuracy degrading at distance or with larger-volume darts.
  • Velocity and impact energy concerns — darts can cause tissue trauma, fractures, or excessive penetration, especially in sensitive species or thinner-skinned animals.
  • Aerodynamic and stabilization issues leading to inaccurate shots or dart failure.
  • Volume/payload constraints in many systems.
  • Need for precise pressure/velocity calibration; risk to operators from ballistic properties.
  • Stress to animals from close approach or multiple darts; prep time requirements; and variable induction/recovery depending on formulation and delivery consistency.


Recent experiments (e.g., drone-based dart delivery) aim to increase standoff distance and safety but introduce their own complexities like gravity-drop limitations or regulatory hurdles.


How This Patent’s System Could Improve Veterinary Outcomes


The invention’s design — spiraling ballistic flight for accuracy and stability, rotatable hub for kinetic energy dissipation, curved/spiral offset hypodermic needles that leverage rotation for controlled “drilling” penetration and injection, optional staged energy absorption (e.g., leading airfoil/nose cone), and compatibility with standard firearms/launchers — directly targets many of these pain points. It supports low-to-medium velocities (optimally 300–800 fps) and practical ranges (10–100+ yards) while prioritizing minimal harm.


Key potential veterinary advantages:

  • Greater standoff distance and safety for handlers — Critical when dealing with dangerous, stressed, or unpredictable animals (e.g., large carnivores, ungulates, or injured wildlife). Reduces risk of injury to veterinarians, wildlife officers, or rescue teams.
  • Improved accuracy and consistency via spin stabilization — Better hit rates at medium-to-longer ranges, fewer missed shots or multiple darts needed, and less stress/prolonged pursuit for the animal.
  • Safer impact profile — Energy dissipation mechanisms (rotatable hub allowing continued housing spin, staged degradation) could reduce bruising, penetration trauma, or skeletal injury compared to conventional darts, improving animal welfare.
  • Effective injection mechanics — Curved or spiraling needles (with optional barbs) designed for subdermal bolus delivery; rotation assists clean penetration and may enable reliable dosing even through fur, hide, or feathers.
  • Payload and formulation flexibility — Supports meaningful volumes while managing mass/energy; pairs naturally with stable, long-shelf-life formulations (including the inventor’s related cannabinoid sedation/anesthesia work).
  • Operational practicality — Less pre-assembly in some embodiments; usable with familiar tools (shotguns, rifles, 40 mm launchers); potential for reusable components.


Specific Veterinary Applications

  1. Wildlife Management, Conservation, and Research Remote capture, collaring/tagging, health assessments, disease sampling/vaccination, or relocation of free-ranging animals (deer, bears, big cats, primates, marine mammals, birds, reptiles, etc.). Safer and less stressful than nets, traps, or close darting in remote or rugged terrain. Supports population monitoring, human-wildlife conflict mitigation, and conservation translocations. Non-lethal options for certain management scenarios align with ethical priorities.
  2. Zoo and Captive/Exotic Animal Care Medicating or sedating animals in enclosures for examinations, treatments, minor procedures, or transport without entering the space or using excessive restraint. Particularly valuable for large, dangerous, or highly stressed species where close approach is risky or counterproductive. Could facilitate routine care or emergency interventions with reduced animal anxiety.
  3. Livestock and Farm Animal Husbandry Treating herds or individuals in pastures, feedlots, or extensive grazing systems (e.g., antibiotics, anti-inflammatories, vaccines, or sedatives for procedures like hoof trimming or examinations). Reduces labor, handler risk, and animal stress compared to physical restraint or close handling. Useful during disease outbreaks or in large-scale operations.
  4. Animal Control, Rescue, and Rehabilitation Humane capture/sedation of stray, feral, escaped, or injured animals (including urban wildlife like deer or aggressive dogs). Enables safe transport and treatment; valuable for wildlife rehabilitators and rescue groups, especially in areas with delayed veterinary response. Supports alternatives to lethal methods where appropriate.
  5. Non-Lethal or Specialized Hunting/Management Contexts As noted in the patent, potential in non-lethal sport or management hunting scenarios, or for targeted interventions (e.g., research sampling).

 

Overall Outlook This technology has the potential to meaningfully advance humane veterinary remote delivery by extending practical range and accuracy while improving safety margins for both animals and humans. In professional settings (wildlife agencies, zoos, large-animal practices, rescue organizations), it could become a valuable evolution of current dart systems — reducing stress, injury rates, and operational risks. Near-term impact is most likely in wildlife and zoo contexts, with livestock and rescue uses following validation.

© 2016-2026 Charles Ankner


This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept